ROCKVILLE, Md., Aug. 29, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Jeff Riley, President & Chief Executive Officer, will provide an overview of Synthetic Biologics' lead microbiome-focused drug candidates poised for Phase 3 development during a live presentation scheduled for Tuesday, September 12, 2017 at 8:45 a.m. ET and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the web at http://wsw.com/webcast/rrshq27/syn. After the presentation, a replay will be archived and accessible for 60 days at the same website.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with Synthetic Biologics.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.